tbuckley/cabot-search huggingface dataset:
MIDAM Regimen (Mylotarg + Intermediaite Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.
Authors: Patrice Chevallier, Noel Milpied, Mathilde Hunault-Berger, Richard Garand, Philippe Moreau, Jacques Delaunay, Thierry Guillaume, Jean-Luc Harousseau
Journal: Blood (2006)
Genetic Evidence of a Novel Blood Differentiation Pathway from Lympho-Myeloid Hematopoietic Stem/Progenitor Cells, Independent of Common Myeloid Progenitors.
Authors: Anne Hultquist, Robert Mansson, Mikael Sigvardsson, Jorgen Adolfsson, David Bryder, Liping Yang, Lina Thoren, Sten E.W. Jacobsen
Journal: Blood (2004)
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.
Authors: David Siegel, Donna M Weber, Constantine S. Mitsiades, Meletios A. Dimopoulos, Jean-Luc Harousseau, Syed Rizvi, Jason Howe, David Reiser, Catriona Byrne, Kenneth C. Anderson, Paul Richardson
Journal: Blood (2009)
Serum Tryptase Levels in AML at Diagnosis: A Multicenter Retrospective Study.
Authors: Roberto Cairoli, Carla B. Ripamonti, Simonetta Granata, Alessandro Beghini, Patrizia Colapietro, Giovanni Grillo, Gianpaolo Nadali, Assunta Viola, Chiara Cattaneo, Liliana Intropido, Erika Ravelli, Gianbattista Bertani, Laura Pezzetti, Michele Nichelatti, Silvio Veronese, Alessandro Marocchi, Giuseppe Rossi, Giovanni Pizzolo, Felicetto Ferrara, Annamaria Nosari, Enrica Morra
Journal: Blood (2006)
Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.
Authors: Jorge Cortes, Karen Seiter, Richard Thomas Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina Luger, Bimalangshu Dey, Gary J. Schiller, Dat Pham, Camille N. Abboud, Muthuswamy Krishnamurthy, Archie Brown, Joseph O. Moore
Journal: Blood (2008)
Evaluation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) as An Indicator of Overall Survival, Progression Free Survival, Survival From Relapse
Authors: Bijal D. Shah, Jennifer L. Cultrera, Lubomir Sokol, Paul A. Chervenick, Celeste M. Bello, Elizabeth M. Sagatys, Lynn C. Moscinski, Ling Zhang, Jianguo Tao, Eduardo M. Sotomayor
Journal: Blood (2010)
Risk Stratification without a Liver Biopsy of Patients with β Thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant.
Authors: Vikram Mathews, Kavitha M Lakshmi, Auro Viswabandya, Biju George, Mammen Chandy, Alok Srivastava
Journal: Blood (2009)
Identifying the Molecular Mechanisms By Which Disruptor of Telomere Silencing 1-like (DOT1L), a Histone 3, Lysine 79 (H3K79) Methyltransferase, Regulates Mammalian Hematopoiesis
Authors: Carrie A. Malcom, Joanna Piasecka-Srader, Nehemiah S. Alvarez, Patrick E. Fields
Journal: Blood (2016)
Acute Myeloid Leukemia: Challenges and Real World Data from India
Authors: Chepsy C Philip, Biju Geoge, Abhijeet Ganapule, Kavitha M Lakshmi, Fouzia N Abubacker, Aby Abraham, Auro Viswabandya, Vivi M Srivastava, Alok Srivastava, Poonkuzhali Balasubramanian, Vikram Mathews
Journal: Blood (2014)
Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System
Authors: Leyla Shune, Zohar Sachs, Todd E. Defor, Michelle Dolan, Daniel J. Weisdorf, Celalettin Ustun, Erica D. Warlick
Journal: Blood (2012)
MMP-2 and MMP-9 Secreted by Leukemic Cells Increase the Permeability of Blood-Brain Barrier by Disrupting Tight Junction Proteins In Central Nervous System Leukemia
Authors: Sa-ran Feng, Zi-Xing Chen, Jian-nong Cen, Hong-jie Shen, Li Yao, Yuan-yuan Wang, Xiao-fei Qi, Su-ning Chen
Journal: Blood (2010)
Splenic Marginal Zone Lymphoma in an East Mediterranean/Middle Eastern Population Cohort: Possible Association with Hepatitis B Instead of Hepatitis C Virus As an Etiologic and Prognostic Factor (ThREG-NHL01 Study)
Authors: Tuncay Aslan, Evren Ozdemir, Aysegul Uner, Elif Gungor, Nevin Alayvaz Aslan, Esra Yildizhan, Abdullah Agit, Serdal Korkmaz, Gulsum Akgun Cagliyan, Ibrahim Barista, Esra Ozhamam, Gulsum Emel Pamuk, Mehmet Turgut, Bulent Eser, Gulsum Ozet, Rahsan Yıldırım, Yahya Buyukasik
Journal: Blood (2016)
Serum Albumin and Peripheral Blood Neutrophils at Diagnosis May Provide Additional Prognostic Information in Primary Nodal Diffuse Large-B-Cell Lymphoma Patients Treated with R-CHOP
Authors: Branimir Spassov, Donka Vassileva, Georgi Mihaylov, Gueorgui Balatzenko, Margarita Guenova
Journal: Blood (2016)
Determination of meningioma brain tissue grades using Raman hyperspectral imaging
Authors: Camilo De Lelis Medeiros De Morais, Taha Lilo, Katherine Ashton, Charles Davis, Timothy Dawson, Nihal Gurusinghe, Francis Martin
Journal: Neuro-Oncology (2019)

Abstract Raman spectroscopy is a powerful tool used to analyse biological materials, where spectral biomarkers such as proteins (1500–1700 cm-1), carbohydrates (470–1200 cm-1) and phosphate groups of DNA (980, 1080–1240 cm-1) can be detected. A major advantage is that it is reagent-free and unaffected by water interference, which is ideal for biological applications. Raman hyperspectral imaging combines the chemical sensitivity of this spectrochemical technique with spatially distributed information. Herein, Raman microspectroscopy imaging (50 × 50 μm tissue area, 50× magnification, 50% laser power, 0.1 ms exposure time, 780–1858 cm-1 spectral range) was used to investigate 79 brain tissue samples (sourced from the Brain Tumour North West) in order to differentiate meningioma Grade I (n=55) versus Grade II (n=24). Meningioma is the commonest type of brain tumour with the majority of them being benign tumours (Grade I) whilst a few are aggressive or malignant (Grade II). Grade II tumours have a poor prognosis by their nature, hence new sensitive diagnostic tools are essential. Using partial least squares discriminant analysis (PLS-DA) with 20 LVs (99% explained variance), we were able to differentiate Grade I versus Grade II meningioma with a classification accuracy of 99% in an internal validation set of 23 samples (16 Grade I, seven Grade II); this was with an accuracy of 85% for an external test set of similar size. These findings highlight the potential of Raman hyperspectral imaging for differentiation of meningioma tumours.
Early Phase Administration of Hematopoietic Stem Cell Transplantation to Prevent Early Relapse for Infants with Acute Lymphoblastic Leukemia and MLL Gene Rearrangement; a Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL03
Authors: Katsuyoshi Koh, Daisuke Tomizawa, Akiko Moriya Saito, Tomoyuki Watanabe, Atsushi Ogawa, Takashi Sato, Masahiro Hirayama, Yoshihiro Takahashi, Yutaka Saikawa, Takako Miyamura, Koji Kato, Kanji Sugita, Takeyuki Sato, Tomohiko Taki, Shuki Mizutani, Masahito Tsurusawa, Keizo Horibe, Eiichi Ishii
Journal: Blood (2010)
Gain-of-Function Mutations of GATA-2 in Acute Myeloid Transformation of Chronic Myeloid Leukemia.
Authors: Su-Jiang Zhang, Li-Yuan Ma, Qiu-Hua Huang, Guo Li, Bai-Wei Gu, Xiao-Dong Gao, Jing-Yi Shi, Yue-Ying Wang, Li Gao, Xun Cai, Rui-Bao Ren, Zhu Chen, Sai-Juan Chen
Journal: Blood (2007)
Umbilical Cord Blood Transplantation and Delay Engraftment Are Associated with Increased Risks of Diffuse Alveolar Hemorrhage
Authors: Ezzideen Barjes Alrawi, Fatma Keklik., Qing Cao, Nelli Bejanyan, Margaret L. MacMillan, Mukta Arora, Erica D. Warlick, Claudio G Brunstein, Daniel J. Weisdorf, Celalettin Ustun
Journal: Blood (2016)
Fresh Frozen Plasma Transfusion Ameliorates INR and aPTT but Does Not Increase Thrombomodulin-Corrected Thrombin Generation in Patients with Cirrhosis
Authors: Amanda Bruder Rassi, Tania RFR Rocha, Alberto Q Farias, Livia Caroline Barbosa Mariano, Elbio Antonio D'Amico
Journal: Blood (2016)
Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning
Authors: Melinda A Biernacki, Maureen Okam, Shalini Shenoy, Lakshmanan Krishnamurti, Mitchell E. Horwitz, Donna Neuberg, Joseph H. Antin, Catherine J Wu
Journal: Blood (2010)
Higher Incidence and Risk of Developing Second Solid Cancers (SSC) after Haematopoetic Stem Cell Transplantation (HSCT) As Compared to General Population
Authors: Samar Kulkarni, John Murray, Charlotte Smith, Stephanie Cleaver, Michael Dennis, Jim Cavet, Tim Somervaille, Anna Z Castleton, Daniel Wiseman, Joanna Tomlins, Kaz Mamat, Angie Leather, Rita Angelica, Adrian Bloor
Journal: Blood (2016)
Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis
Authors: Carmen M Alonso*, Marta Llop*, Mariam Ibáñez, Jose Cervera, Esperanza Such, Eva Villamon, Sarai Palanca, Inmaculada de Juan, Rosa Murria, Blanca de Unamuno, Laia Pedrola, Ivan Martin, Pau Montesinos, Pascual Bolufer, Miguel A. Sanz, Eva Barragan
Journal: Blood (2015)
Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).
Authors: Amrita Krishnan, Andrew Raubitschek, Auayporn P. Nademanee, N. Kogut, Leslie Popplewell, Ni-Chun Tsai, Joycelynne Palmer, Jennifer Simpson, Laura Federico, Dave Yamauchi, Stephen J. Forman
Journal: Blood (2009)
Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup
Authors: Antonio Palumbo, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Douglas Joshua
Journal: Blood (2015)
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
Authors: James W. Welsh, John V. Heymach, Dawei Chen, Vivek Verma, Taylor R. Cushman, Kenneth R. Hess, Girish Shroff, Chad Tang, Ferdinandos Skoulidis, Melenda Jeter, Hari Menon, Quynh-Nhu Nguyen, Joe Y. Chang, Mehmet Altan, Vassiliki A. Papadimitrakopoulou, George R. Simon, Uma Raju, Lauren Byers, Bonnie Glisson
Journal: Journal of Thoracic Oncology (2019)
Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis
Authors: Tobias Herold, Klaus H. Metzeler, Sebastian Vosberg, Stephanie Schneider, Max Hubmann, Evelyn Zellmeier, Bianka Ksienzyk, Vindi Jurinovic, Zlatana Pasalic, Purvi M. Kakadia, Annika Dufour, Alexander Graf, Stefan Krebs, Helmut Blum, Cristina Sauerland, Thomas Büchner, Wolfgang E. Berdel, Bernhard J. Woermann, Ulrich Mansmann, Wolfgang Hiddemann, Stefan K. Bohlander, Karsten Spiekermann, Philipp A Greif
Journal: Blood (2013)
Maternal Gestational Diabetes Mellitus and Newborn DNA Methylation: Findings From the Pregnancy and Childhood Epigenetics Consortium
Authors: Caitlin G. Howe, Bianca Cox, Ruby Fore, James Jungius, Tuomas Kvist, Samantha Lent, Harriet E. Miles, Lucas A. Salas, Sheryl Rifas-Shiman, Anne P. Starling, Paul Yousefi, Christine Ladd-Acosta, Andrea Baccarelli, Elisabeth B. Binder, Vaia Lida Chatzi, Darina Czamara, Dana Dabelea, Dawn L. DeMeo, Akram Ghantous, Zdenko Herceg, Eero Kajantie, Jari M.T. Lahti, Debbie A. Lawlor, Augusto Litonjua, Tim S. Nawrot, Ellen A. Nohr, Emily Oken, Costanza Pizzi, Michelle Plusquin, Katri Räikkönen, Caroline L. Relton, Gemma C. Sharp, Thorkild I.A. Sørensen, Jordi Sunyer, Martine Vrijheid, Weiming Zhang, Marie-France Hivert, Carrie V. Breton
Journal: Diabetes Care (2019)

OBJECTIVE Maternal gestational diabetes mellitus (GDM) has been associated with adverse outcomes in the offspring. Growing evidence suggests that the epigenome may play a role, but most previous studies have been small and adjusted for few covariates. The current study meta-analyzed the association between maternal GDM and cord blood DNA methylation in the Pregnancy and Childhood Epigenetics (PACE) consortium. RESEARCH DESIGN AND METHODS Seven pregnancy cohorts (3,677 mother-newborn pairs [317 with GDM]) contributed results from epigenome-wide association studies, using DNA methylation data acquired by the Infinium HumanMethylation450 BeadChip array. Associations between GDM and DNA methylation were examined using robust linear regression, with adjustment for potential confounders. Fixed-effects meta-analyses were performed using METAL. Differentially methylated regions (DMRs) were identified by taking the intersection of results obtained using two regional approaches: comb-p and DMRcate. RESULTS Two DMRs were identified by both comb-p and DMRcate. Both regions were hypomethylated in newborns exposed to GDM in utero compared with control subjects. One DMR (chr 1: 248100345–248100614) was located in the OR2L13 promoter, and the other (chr 10: 135341870–135342620) was located in the gene body of CYP2E1. Individual CpG analyses did not reveal any differentially methylated loci based on a false discovery rate–adjusted P value threshold of 0.05. CONCLUSIONS Maternal GDM was associated with lower cord blood methylation levels within two regions, including the promoter of OR2L13, a gene associated with autism spectrum disorder, and the gene body of CYP2E1, which is upregulated in type 1 and type 2 diabetes. Future studies are needed to understand whether these associations are causal and possible health consequences.
Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis
Authors: Heather Cameron, Melissa Thompson, John-Paul Marino, Michael Duong, Ursula Becker, Christof Wiesner
Journal: Blood (2014)
Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice
Authors: Kotaro Shide, Takuro Kameda, Masaaki Sekine, Ayako Kamiunten, Keiichi Akizuki, Yuki Tahira, Tomonori Hidaka, Yoko Kubuki, Arata Honda, Akira Sawaguchi, Akira Kitanaka, Kazuya Shimoda
Journal: Blood (2016)
Initial and Confirmation Analyses of a Detailed Comorbidity and Organ Function Assessment In 593 Multiple Myeloma (MM) Patients (pts) Identify the Freiburger Comorbidity Index (FCI) as a Non-Weighted, Simple, Concise and Cost Effective Comorbidity Score Consisting of 3 Factors Only: Proposal of a Valuable New Tool In MM-Risk Assessment
Authors: Meike Terhorst, Martina Kleber, David De Pasquale, Gabriele Ihorst, Monika Engelhardt
Journal: Blood (2010)
Altered Endothelial Cells Properties and Platelets Activity in Treatment NaïVe Patients with Multiple Myeloma (MM ) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications
Authors: Lidia Usnarska-Zubkiewicz, Maria Podolak-Dawidziak, Urszula Zaleska-Dorobisz, Magdalena Olszewska-Szopa, Iwona Prajs, Jakub Debski, Kazimierz Kuliczkowski, Tadeusz Robak
Journal: Blood (2016)
Growth Factor Independent-1 (Gfi1) Is Critically Required for T-Cell Acute Lymphoblastic Leukemia (T-ALL) Tumor Initiation and Maintenance
Authors: James D. Phelan, Cyrus Khandanpour, Shane Horman, Marie-Claude Gaudreau, Jinfang Zhu, William E Paul, Ulrich Dührsen, H. Leighton Grimes, Tarik Moroy
Journal: Blood (2010)
First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial
Authors: Paul Fields, Andrew Webb, Christopher FE Pocock, William Townsend, Paul Smith, Amy Kirkwood, Nadjet El-Mehidi, Peter W Johnson, John Radford, David C Linch, David Cunningham
Journal: Blood (2011)
Preliminary Safety and Efficacy Results from an International Phase 3b Study for Expanded Access to Bortezomib in 624 Patients with Relapsed and/or Refractory Multiple Myeloma.
Authors: Joseph R. Mikhael, Andrew Belch, Miles Prince, Maria Nambo Lucio, Angelo Maiolino, Alessandro Corso, Maria Teresa Petrucci, Komarnicki Mieczyslaw, A. Keith Stewart
Journal: Blood (2006)
Impact on Iron Removal of Dose Reduction for Non-Progressive Serum Creatinine Increases during Treatment with the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670).
Authors: N. Gattermann, N. Zoumbos, E. Angelucci, G. Drelichman, J. Siegel, E. Glimm, D. Alberti
Journal: Blood (2006)
Generation of Cytomegalovirus (CMV)-Specific CD4 and CD8 T Cell Lines Using Protein-Spanning Pools of pp65 and IE1 Derived Peptides.
Authors: Erica Dander, Giuseppina Li Pira, Ettore Biagi, Fabrizio Manca, Andrea Biondi, Giovanna D’Amico
Journal: Blood (2005)
Hospital-Acquired Venous Thromboembolism (VTE): A Retrospective Consecutive Case Series
Authors: Brandyn Daniel Lau, Elliott R Haut, Bhunesh Maheshwari, Peggy S Kraus, Deborah Hobson, Howard Carolan, Kenneth Shermock, Aileen Almario, Chepkorir Maritim, Michael B. Streiff
Journal: Blood (2012)
Update on the Implementation of NCCN Guidelines for Distress Management by NCCN Member Institutions
Authors: Kristine A. Donovan, Teresa L. Deshields, Cheyenne Corbett, Michelle B. Riba
Journal: Journal of the National Comprehensive Cancer Network (2019)

The first NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Distress Management were published in 1999. Since then, a number of other organizations have advocated for distress screening. Previous surveys of distress screening showed modest progress in implementation of the NCCN Guidelines for Distress Management by NCCN Member Institutions (MIs); this review examined whether further progress has been made. Representatives appointed to the NCCN Distress Management Panel or their designee were asked to complete an online survey in the summer of 2018. The survey was developed based on similar surveys performed in 2005 and 2012 and a survey of psychosocial staffing conducted in NCCN MIs in 2012. New items solicited details about triaging, rescreening, formal screening protocols, and tracking of distressed patients. The survey was completed by representatives from 23 of 27 NCCN MIs (85%). Among the responding institutions, 20 (87%) currently conduct routine screening for distress and 3 are piloting routine screening. All respondents reported use of a self-report measure to screen for distress, with the Distress Thermometer most often used. A total of 70% of respondents rescreen patients for distress and 83% reported having a formal distress screening protocol in place. Once triaged, 65% of institutions who routinely screen for distress track clinical contacts and referrals; 70% track rates of adherence to screening protocols. Findings suggest wide acceptance and implementation of the NCCN Guidelines. Most respondents reported the existence of a formal distress screening protocol, with routine tracking of clinical contacts and referrals and rates of protocol adherence. Clinical experience and the American College of Surgeons Commission on Cancer accreditation standard for cancer centers appear to have resulted in greater adoption and implementation of the guidelines, but considerable opportunities for improvement remain.
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin’s Lymphoma
Authors: Scott F. Huntington, Jessica R. Hoag, Rong Wang, Amer M. Zeidan, Smith Giri, Steven D. Gore, Xiaomei Ma, Cary P. Gross, Amy J. Davidoff
Journal: Journal of the National Comprehensive Cancer Network (2019)

Provider experience, or clinical volume, is associated with improved outcomes in many complex healthcare settings. Despite increased complexity of anticancer therapies, studies evaluating physician-level experience and cancer treatment outcomes are lacking.A population-based study was conducted of older adults (aged ≥66 years) diagnosed with B-cell non-Hodgkin's lymphoma in 2004 through 2011 using SEER-Medicare data. Analysis focused on outcomes in patients receiving rituximab, the first approved monoclonal anticancer immunotherapy. We hypothesized that lower physician experience using rituximab and managing its infusion-related reactions would be associated with early treatment discontinuation. A 12-month look-back from each initiation of rituximab was used to categorize physician volume (0, 1-2, or ≥3 initiations per year). Modified Poisson regression was used to account for provider-level correlation and estimated relative risk (RR) of early rituximab discontinuation (<3 cycles within 180 days of rituximab initiation). Cox proportional hazards were used to measure the impact of rituximab discontinuation on survival.Among 15,110 patients who initiated rituximab with 2,684 physicians, 7.6% experienced early rituximab discontinuation. Approximately one-fourth of patients (26.1%) initiated rituximab with a physician who had no rituximab initiations during the preceding 12 months. Compared with patients treated by physicians who had ≥3 rituximab initiations in the prior year, those treated by physicians without initiations were 57% more likely to experience early discontinuation (adjusted RR [aRR], 1.57; 95% CI, 1.35-1.82; P<.001 for 0 vs ≥3, and aRR, 1.19; 95% CI, 1.03-1.37; P=.02 for 1-2 vs ≥3). Additionally, rituximab discontinuation was associated with higher risk of death (adjusted hazard ratio, 1.39; 95% CI, 1.28-1.52; P<.001).Lower oncologist experience with rituximab was associated with increased risk of early rituximab discontinuation in Medicare beneficiaries with non-Hodgkin's lymphoma. Physician-level volume may be an important factor in providing high-quality cancer care in the modern era.
The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases
Authors: Monica S Thakar, Brent R. Logan, Marcelo C. Pasquini, Philip L. McCarthy, Vincent T Ho, Kenneth R. Cooke, Xiaochun Zhu, J. Douglas Rizzo, Mohamed L. Sorror
Journal: Blood (2012)
Splenectomy in Patients with Myeloproliferative Neoplasms (MPNs): Efficacy, Complications and Impact On Survival and Transformation.
Authors: Fabio P S Santos, Constantine S. Tam, Hagop M. Kantarjian, Jorge E. Cortes, Deborah A. Thomas, Raphael E Pollock, Srdan Verstovsek
Journal: Blood (2012)
Simultaneous Cytokine Analysis by Cytometric Bead Array (CBA) Allows More Sensitive Detection of Leukemia-Reactive T Cells in Patients with Chronic Myeloid Leukemia.
Authors: Jörg Westermann, Antje van Lessen, Claudia Schlimper, Gökben Baskaynak, Philipp Le Coutre, Bernd Dörken, Antonio Pezzutto
Journal: Blood (2005)
Genetic Rearrangements of FOXP1 Are Restricted to a Subset of Agressive B Cell Lymphoma with Extranodal Presentation.
Authors: Eugenia Haralambieva, Patrick Adam, Irina Eichelbroenner, Joerg Kalla, Andreas Rosenwald, Tiemo Katzenberger, Sylvia Hoeller, Alison H. Banham, Hans Konrad Mueller-Hermelink, German Ott
Journal: Blood (2005)
Posttransplant Lymphoproliferative Disorders (PTLD) After Renal Transplantation: Focus on HLA Antigens
Authors: Charlotte Strandhave, Kaj Anker Jørgensen, Knud Bendix, Bente Jespersen, Robert Schou Pedersen, Esben Søndergaard, Leif Spange Mortensen, Francesco d'Amore
Journal: Blood (2010)
Clinical Relevance of Changes of ROS/Peroxiredoxin 1 (Prx1) and Glutathione Peroxidase 1 (Gpx1) Level In AML Primary Cells before and after Induction Chemotherapy
Authors: Eun Mi Nam, Jee Young Ahn, Jung Yeon Cho, Yeung-Chul Mun, Kyoung Eun Lee, Jung Won Huh, Hyun Ae Woo, Sue Goo Rhee, Chu-Myong Seong
Journal: Blood (2010)
Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status
Authors: Junji Koyama, Tomoki Kimura, Hajime Oi, Yasuhiko Yamano, Toshiki Yokoyama, Toshiaki Matsuda, Kensuke Kataoka, Reiko Matsuzawa, Jun Fukihara, Koji Sakamoto, Masahiro Morise, Naozumi Hashimoto, Yasuhiro Kondoh, Yoshinori Hasegawa
Journal: Annals of Oncology (2019)